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ABSTRACT
The way that allogeneic hematopoietic cells are rejected is not completely understood. Regimen-resistant
populations, including natural killer (NK) cells and lymphocytes, are thought to mediate the allograft barrier.
In this report, the mechanism by which recipient cell populations resist engraftment of purified allogeneic
hematopoietic stem cells (HSCs) was examined in mice. To define the immunoregulatory pathways involved in
allogeneic hematopoietic cell resistance, HSC transplantations were performed in immune-defective recipi-
ents. Recipients were wild-type mice treated with -NK cell antibodies or knockout strain mice lacking
expression of CD8, perforin, Fas ligand, or 1 of the following cytokines: tumor necrosis factor , transforming
growth factor , interferon , interleukin 4, or interleukin 10. Elimination of a single cytotoxic pathway was
ineffective in reducing engraftment resistance, although mice treated with a polyclonal antibody that recog-
nizes NK-cell determinants or CD8 expression showed a profound reduction in the engraftment barrier.
Posttransplantation chimerism analysis revealed regeneration of host hematopoiesis in some experimental
groups. These studies show, for the first time, that elimination of selected cytokines does not alter allogeneic
hematopoietic resistance. Furthermore, the chimerism data reinforce the importance of competition for HSC
niches in conjunction with immune mechanisms in resistance to long-term HSC engraftment.
© 2005 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
In allogeneic hematopoietic cell transplantation
AHCT) for the treatment of hematologic malignan-
ies or bone marrow (BM) failure states, the beneﬁts
onferred by the hematopoietic graft are to both re-
lace the diseased cells in the recipient and mediate
raft-versus-tumor effects [1,2]. Unfortunately, con-
entional hematopoietic grafts can also induce graft-
ersus-host disease (GVHD), which remains an im-
ortant cause of morbidity and mortality after AHCT
3,4]. GVHD occurs when mature immune cells, pri-
arily T lymphocytes, contained within a hematopoi-
tic graft recognize and direct responses against
ealthy host tissues. Previous attempts to eliminate
raft T cells resulted in reduced GVHD; however, t
B&MTigniﬁcant increases in graft failure were also observed
5-9]. Graft failure that occurs in recipients condi-
ioned for transplantation with myeloablative regi-
ens is invariably fatal [6,10,11]. Thus, most trans-
lant centers continue to use unmanipulated BM or
obilized peripheral blood despite the risk of GVHD,
nd resistance to engraftment remains a major obsta-
le to the future use of engineered hematopoietic
rafts composed of puriﬁed populations.
The way that allogeneic hematopoietic grafts are
ecognized and eliminated by recipients is not com-
letely understood. The studies of Cudkowicz and
ennett [12] and Kiessling et al. [13] and later of
ennett [14] showed that resistance to hematopoietic
ells involves biological processes distinct from solid
issue rejection. Differences in the genetics and the
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2ell populations that mediate resistance have been
escribed [14]. Studies in mice show that whereas
olid organs transplanted from inbred strain parents
nto F(1) offspring uniformly result in graft accep-
ance, this genetic pattern of acceptance is not always
bserved for hematopoietic grafts, because F(1) off-
pring can demonstrate vigorous resistance—a phe-
omenon initially termed hybrid histocompatibility
Hh) resistance [14]. Hh was later renamed to hemo-
oietic histocompatibility 1 (a more broadly applicable
erm) when similar major histocompatibility complex
MHC)–linked patterns of resistance were noted to
pply to BM allografts. Hh resistance occurs despite
onditioning of recipients with lethal doses of radia-
ion (XRT), which is a treatment that results in nearly
omplete elimination of host hematopoietic cells, in-
luding stem and progenitor cells and T and B lym-
hocytes. It is known that natural killer (NK) cells
lay a central role in Hh resistance [15-17]. However,
K cells do not participate signiﬁcantly in solid organ
ransplant rejection [18,19].
Because NK cells kill susceptible targets, it has
een proposed that the cytotoxic functions of NK cells
ediate hematopoietic cell resistance [19-21]. Three
rincipal cytotoxic pathways can be used. One de-
ends on exocytosis of granules containing perforin
nd granzymes [22-26], the second on Fas (Apo-1;
D95) and its ligand (FasL) [27-30], and the third on
ecreted molecules [31-34]. Prior reports showed that
n animals lacking intact pathways of granule and/or
as killing, resistance to hematopoietic cell engraft-
ent was unimpaired [35-39]. Thus, it was suggested
hat certain lymphokines secreted by NK cells with
nown cytotoxic or growth-inhibitory effects are the
rimary effectors of hematopoietic cell resistance.
In this report, the mechanisms by which NK and
ther recipient cell populations resist engraftment of
uriﬁed hematopoietic stem cells (HSCs) were exam-
ned in mice. Analogous to the clinical experience with
cell–depleted BM, HSCs are more vigorously re-
isted as compared with unfractionated BM [40].
ere, puriﬁed allogeneic HSCs devoid of facilitating
ells that could confound the analysis were trans-
lanted across a highly resistant mouse strain combi-
ation into wild-type mice or mice with genetic de-
ects in expression of speciﬁc secreted molecules,
ncluding tumor necrosis factor (TNF)–, transform-
ng growth factor (TGF)–, and polarizing T-helper
Th)1 and Th2 cytokines. perforin or FasL expression
ere also used as recipients. We observed that elimi-
ation of any 1 cytotoxic pathway tested here did not
educe the barrier to allogeneic HSC engraftment. In
ome recipient groups reconstitution of host hemato-
oiesis was noted, suggesting that the HSC barrier is
composite of both immune-mediated resistance and
ompetition for stem cell niches. cATERIALS AND METHODS
ice
Animal care was provided in accordance with the
rocedures outlined in the Guide for the Care and Use
f Laboratory Animals (NIH Publication 86-23; 1985).
SC donors were 5- to 7-week-old AKR/J (H2k)
train mice. Recipient mice were 8- to 16-week-old
ild-type C57BL/6 (B6.WT, H2b) or genetically
ngineered knockout mice for the following genes
n the C57BL/6 background: B6.IL-4/ (B6.129P2-
l4tmlCgn), B6.IL-10/ (B6.129P2-Il10tmlCgn),
6.TNF-/ (B6.129-Tnfrsf1atm1Mak), B6.TGF-
/ (B6.129S2-Tgfb1tm1Doe), B6.IFN-/ (B6.129S7-
fngtm1Ts), B6.pfp/ (C57BL/6-pfptm1Sdz), and B6.gld
B6.Smn.C3H-Faslgld). Recipients were purchased from
ackson Laboratory (Bar Harbor, ME), and founder
ice were then bred and maintained in the Stanford
niversity Department of Laboratory Animal Medicine
nder pathogen-free conditions by using ﬁlter-top cages
nd temperature-controlled and light-cycled rooms.
SC Purification
Whole BM cells were obtained from donors by
ushing tibias and femurs with Hanks balanced salt
olution (Applied Scientiﬁc, San Francisco, CA) sup-
lemented with 2% fetal calf serum (Gibco BRL,
arlsbad, CA) by using a 25-gauge needle and syringe.
SCs were isolated by a modiﬁcation of the method
escribed by Spangrude et al. [41]. In brief, whole BM
ells were enriched for c-Kit (CD 117, stem cell factor
eceptor) by staining with a biotinylated c-Kit mono-
lonal antibody (mAb) and run through a magnetically
ctivated cell-sorting streptavidin-conjugated mag-
etic bead column (Miltenyi Biotec, Auburn, CA).
he c-Kit–enriched fraction was stained with ﬂuores-
ein isothiocyanate (FITC)–conjugated –Thy-1.1
19E5), Texas red–conjugated –Sca-1 (E13-161),
llophycocyanin-conjugated –c-Kit (2B8), and a mix-
ure of phycoerythrin-conjugated lineage-speciﬁc
Abs, as follows: -B220 (6B2), -CD3 (145-2C11),
-CD5 (53-7.8), -CD4 (GK-1.5), -CD8 (53-6.7),
–Gr-1 (8C5), –Mac-1 (M1/70), and -TER119
TER199). The conjugated mAbs were the gift of Dr.
. Weissman, of the Department of Pathology, Stan-
ord University, except for -CD3 mAb (145-2C11)
nd -CD8 mAb (53-6.7), which were obtained from
harmingen (San Diego, CA). Propidium iodide stain
t 1 mg/mL was used to exclude dead cells. Cells were
orted on a dual-laser Vantage sorter (Becton Dickin-
on, Mountain View, CA) made available through the
uorescence-activated cell sorting (FACS) shared user
roup at Stanford University. Veriﬁcation of sorted
ells was obtained by ungated reanalysis. After sorting
or FITClo, Texas redhi, allophycocyaninhi, and phy-
oerythrin/lo, the c-KitThy-1loLin/loSca (KTLS
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Resistance to Allogeneic HSC Engraftment
BSCs) cells were checked by FACS reanalysis and
etermined to be 99% pure.
ecipient Preparation and HSC Transplantation
Recipient mice were conditioned for transplanta-
ion with lethal XRT on day 0 relative to transplan-
ation at a total dose of 950 cGy. A Phillips unit
rradiator (250 kV; 15 mA) was used to deliver the
RT in 2 divided (475 cGy each) doses 3 to 4 hours
part. After XRT, mice were maintained on antibiotic
ater containing 106 U/L of polymyxin B sulfate and
g/L neomycin sulfate. Antibody-treated mice re-
eived -ASGM1 (WAKO Chemicals, Dallas, TX) at
0 g intravenously on day 7 and by intraperitoneal
njection on day 1. Puriﬁed HSCs were injected on
ay 0 in titrated numbers (300, 1000, 3000, and 6000)
n a volume of 100 L per mouse. Cells were injected
nto the suborbital venous plexus of recipient mice.
he biological activity of the HSC transplant was
econﬁrmed by injection of 100 or 200 cells into
ethally irradiated congenic recipients (AKR/Cu;
2k), which were killed for day 12 spleen colony-
ormation unit assay analysis (data not shown).
etection of Hematopoietic Chimerism
Chimerism was assessed at 6 weeks after trans-
lantation by FACS analysis of erythrocyte-depleted
eripheral blood with donor-speciﬁc staining for the
HC class I H2k markers versus B cells (-B220),
ranulocytes (–Gr-1), macrophages/monocytes (–
ac-1), T cells (-CD3), and NK cells (-DX5); all
ntibodies were obtained from Pharmingen. FACS
nalysis was performed by a modiﬁed FACS II system
Becton Dickinson) equipped with logarithmic ampli-
ers. Data are presented as contour plots on log-10
cales of increasing green and red ﬂuorescence inten-
ity.
ubset Staining Analysis
Splenocytes, peripheral blood, and BM cells from
ice in selected treatment groups were analyzed by a
-step FACS staining for -ASGM1 versus the fol-
owing lineage subset markers: CD3, CD4, CD8,
r-1, NK1.1, and Mac-1. Unconjugated -ASGM1
ntibody was used as the ﬁrst step, followed by 2
ashes in media. A second step, FITC-labeled goat
nti-rabbit mAb (GAR-FITC), was then added. The
ineage subset mAbs (directly conjugated to phyco-
rythrin) were then added as the third staining step.
taining with GAR-FITC mAb alone was used to rule
ut nonspeciﬁc binding.
tatistical Analysis
For each HSC dose, the 100-day survival experi-
nce was compared between the control and each
reatment group. The log-rank test was used, and the w
B&MTominal P values are reported. When separate exper-
ments were performed, the P values reﬂect the results
f each individual experiment.
ESULTS
uantitation of the Barrier to Allogeneic HSC
ngraftment
In a prior report we demonstrated in several allo-
eneic mouse strain combinations that the relative
esistance to engraftment of puriﬁed HSCs can be
easured by the numbers of HSCs needed to rescue
ethally irradiated recipients [40]. HSC transplanta-
ion in syngeneic or CD45 congenic mice requires
nly 100 to 200 HSCs for rescue [41], and, in general,
s the genetic disparity increases between donor and
ecipient, more HSCs are required. In this study, an
HC-mismatched strain combination of AKR/J
H2k) into B6.WT (H2b) mice was selected so that the
any immune-defective mice that exist on the
57BL/6 background could be used as recipients.
ecause resistance to long-term engraftment of KTLS
SC was not previously characterized in this strain
ombination, rescue of irradiated B6.WT mice was
ested by infusion of titrated numbers of AKR/J
SCs. Recipients were followed up for 90-day sur-
ival and evaluated for peripheral blood chimerism.
urvival data combined from 2 separate experiments
re shown in Figure 1A. A total of 6000 AKR/J HSCs
escued 70% of B6.WT mice from aplasia, whereas
000 HSCs rescued only 10%, which correlated with
relatively high level of resistance as compared with
nother MHC-mismatched strain combination
B6.WT [H2b] into BALB/c [H2d]). In B6.WT into
ALB/c mice, we previously noted that 6000 HSCs
escued all recipients and that 3000 HSCs rescued
60% [40]. The blood of surviving AKR/J into
6.WT recipients was analyzed by FACS analysis at 6
eeks after transplantation. Figure 1B is a represen-
ative proﬁle of the peripheral blood chimerism of 1 of
hese B6.WT recipients. Similar to our observations
n other mouse strain combinations [40,42], lethally
rradiated, HSC-engrafted mice demonstrated signif-
cant levels of radioresistant host T cells, whereas the
ther white blood cell lineages were nearly all donor
erived (95% donor type).
limination of NK and/or CD8 Cells Reduces
esistance to HSCs
Cells with NK markers and CD8 cells have been
hown to mediate resistance to engraftment of BM in
ifferent mouse strain combinations [19]. To deter-
ine whether the activities of these cell populations
re similarly relevant to the engraftment barrier of
KR/J HSCs into B6.WT mice, B6.WT recipients
ere treated with a polyclonal antibody, -ASGM1,
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4nown to abolish both NK cell and cytotoxic T lym-
hocyte (CTL) activity in vivo [43,44]. Figure 2A
hows that the addition of -ASGM1 resulted in sig-
iﬁcantly improved survival as compared with XRT
nly. A total of 6000 and 3000 AKR/J HSCs rescued
00% of recipients (P 	 .317 and P 	 .013, respec-
igure 1. Survival and chimerism analysis of lethally irradiated mic
HC-mismatched AKR/J (H2k) HSCs were injected into lethal
ransplantation with 300, 1000, 3000, or 6000 HSCs was compared
independent experiments. B, Flow cytometric analysis of periphe
SCs. Detection of hematopoietic chimerism was performed with d
arkers. Shown are proﬁles of B- and T-cell chimerism from the p
ompared with blood proﬁles from control unmanipulated B6.WT a
hereas the B cells are all donor derived.
igure 2. Effects of -ASGM1 polyclonal antibody pretreatment o
cross MHC barriers. Lethally irradiated B6.WT mice received an
eally) before transplantation of titrated doses of MHC-mismatche
00, 1000, 3000, or 6000 HSCs is compared with that of XRT con
ays after intravenous and intraperitoneal administration of 50 g of
etection of ASGM1-expressing T-cell subsets (CD3, CD4, CD8,
nalysis by using -ASGM1 as a staining reagent. Note the depletion of lively), 1000 HSCs rescued 80% of recipients (P 	
007), and 300 HSCs rescued 60% of recipients
P	0.037). Blood chimerism studies at 6 weeks after
ransplantation revealed that most mice that under-
ent transplantation with 1000 HSCs were con-
erted to nearly complete donor type. It is interesting
underwent transplantation across MHC barriers. Titrated doses of
iated B6.WT (H2b) mice. A, Survival of mice that underwent
at of XRT controls (950 cGy of radiation). Results are pooled from
d from B6.WT mice performed 6 weeks after they received 6000
eciﬁc staining for the class I H2 marker (-H2k) versus cell lineage
ral blood of a representative engrafted B6.WT recipient; these are
R/J mice. Note that the engrafted mouse is a partial T-cell chimera,
survival of lethally irradiated mice that underwent transplantation
treatment on day 7 (intravenously) and on day 1 (intraperito-
/J HSCs. A, Survival of mice that underwent transplantation with
50 cGy of radiation). B, Flow cytometric analysis of spleen cells 7
M1 antibody of treated (top) and untreated (bottom) B6.WTmice.
-cell receptor ) and NK cells (NK1.1) was performed by FACSe that
ly irrad
with th
ral bloo
onor-sp
eriphe
nd AKn the
tibody
d AKR
trols (9
-ASG
and Tymphocyte subsets in the -ASGM1 antibody–treated mouse.
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Resistance to Allogeneic HSC Engraftment
Bo note that despite a 60% survival rate in the group of
ice that underwent transplantation with 300 HSCs,
one of the mice was a donor chimera (Table 1).
hus, in this resistant strain combination, targeting
adioresistant ASGM1 host populations signiﬁcantly
ecreased the barrier to HSC engraftment. Further-
ore, at the lower HSC dose, it seemed that although
ntibody pretreatment allowed donor elements to res-
ue mice from aplasia, host hematopoiesis was respon-
ible for long-term recovery.
dentification of -ASGM1 Targets
To identify by phenotype the ASGM1 cells in
he recipients targeted by the antibody, -ASGM1
as used as a staining reagent in FACS analyses. Dou-
le staining of ASGM1 cells was performed by using
D3, CD4, CD8, T-cell receptor , NK1.1, and
ac-1 mAbs. Hematopoietic cell populations from
6.WT mice were analyzed and compared with
6.WT mice treated with -ASGM1 only, XRT only,
r XRT plus -ASGM1. Figure 2B shows the FACS
roﬁles of splenocytes from a representative wild-type
ouse versus a mouse treated 7 days previously with
-ASGM1 only. As expected, the predominant popu-
ation bound by -ASGM1 double-stained for the
K1.1 marker. In addition, the -ASGM1 antibody
lso labeled subsets of other populations, including
D3, CD4, CD8, and Mac-1. Proof that the antibody
esulted in depletion of certain cell subsets rather than
able 1. Survival and Chimerism Analysis after Transplantation of Pu
Recipient
% Surviva
300 KTLS
6.WT 0/0 (10)
-ASGM1–treated B6.WT 60/0 (5)
hown are the percentage of recipients that survived for a given HSC
were prepared for transplantation with lethal XRT with or witho
detection of chimerism with donor-speciﬁc staining for class I H
monocytes (–Mac-1), T cells (–CD3), and NK cells (–DX5) o
Mice deemed chimeric had on average  60% donor-derived
staining, which was, on average,  95% donor type. Nonchime
2 independent experiments.
TLS indicates c-KitThy-1loLin/loSca-1 HSCs.
able 2. Flow Cytometric Analysis of B6.WT Splenocytes
Treatment % Live Cells NK1.1
one 80% 2.9%
-ASGM1 75% 0.2%
RT 18% 14.7%
RT  -ASGM1 33% 0.9%
low cytometric detection of double-stained splenocytes (lineage
performed before and at day 7 after treatment (staining anti
phycoerythrin-conjugated lineage marker). The data shown ar
expressed as percentages of  20 000 recorded cells.
B&MTinding only was derived by staining peripheral blood
nd spleen cells from -ASGM1–treated mice with a
AR second-step reagent that recognizes the
-ASGM1 heavy chain (data not shown). Table 2
ummarizes the depletion data from the 3 treatment
roups. As shown, -ASGM1 not only depletes
K1.1ASGM1 [45] in vivo, but also depletes
D3ASGM1 and CD8ASGM1, but not Mac-
ASGM1, cells. Notably, mice conditioned with
RT alone demonstrated a signiﬁcant relative in-
rease in NK1.1ASGM1 cells, whereas the
D3ASGM1 and CD8ASGM1 cells were mod-
rately to severely reduced. In mice that received the
ombination of XRT plus -ASGM1 (the group with
he lowest level of resistance), the NK1.1ASGM1
opulation was signiﬁcantly depleted, as were the
D3ASGM1 and CD8ASGM1 cells.
D8 Cells and Engraftment Barrier
To assess the contribution of the CD8 cells in-
ependent of NK cells to the engraftment barrier in
his strain combination, HSC transplantations were
erformed in C57BL/6 recipients that lack expression
f the CD8 molecule (B6.CD8/). Figure 3 shows
hat at the lower doses of HSCs, many more
6.CD8/ recipients were rescued as compared
ith wild-type mice. Ninety percent of B6.CD8/
ice that underwent transplantation with 6000 HSCs
P 	 .937 and .134), 70% that underwent transplan-
SCs from AKR/J into B6.WT and –ASGM1–Treated Recipients
nor Chimerism for HSC Dose (No. Mice Analyzed)
0 KTLS 3000 KTLS 6000 KTLS
/0 (10) 10/100 (10) 70/100 (10)
75 (5) 100/100 (5) 100/100 (5)
nd the percentage of these survivors that were chimeric. Recipients
tment with -ASGM1. Flow cytometric analysis was performed for
rker versus B cells (-B220), granulocytes (–Gr-1), macrophages/
ing mice 6 weeks after HSC transplantation against MHC barriers.
T cells. Non–T-cell chimerism was best quantitated by -B220
ients were 
 5% donor type in all lineages. Data are pooled from
geASGM1 Splenocytes
CD4 CD8 Gr-1 Mac-1
4.3% 3.0% 1.3% 3.4%
2.7% 0.7% 0.7% 3.6%
2.8% 1.4% 0.1% 0.7%
2.2% 0.1% 0.1% 27.2%
1) of different treatment groups. A 3-step FACS analysis was
unconjugated -ASGM1, FITC-conjugated goat anti-rabbit, and
a single representative animal in each treatment group and areriﬁed H
l/% Do
100
0
80/
dose a
ut trea
2k ma
f surviv
blood
ric recipLinea
CD3
9.4%
2.4%
1.9%
0.4%
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6ation with 3000 HSCs (P 	 .055 and .002), and 50%
hat underwent transplantation with 1000 HSCs (P 	
011 and .014) survived longer than 100 days after
ransplantation. Reduction in the barrier was not as
rofound as that observed in mice that were treated
ith -ASGM1, because unlike the -ASGM1–
reated group, in which 60% survival was observed at
he 300-HSC dose, none of the B6.CD8/ mice
urvived at the 300-HSC dose level. FACS staining of
he peripheral blood and splenocytes of B6.CD8/
ice before and 7 days after XRT revealed a marked
ercentage increase cells in NK cells after XRT, as
easured by double staining for ASGM1 and
K1.1 (peripheral blood: 0.8% before versus 6.2%
fter XRT; splenocytes: 2.1% before versus 17.1%
fter XRT). Of note, similar to the chimerism data
btained from mice rescued with lower doses of HSCs
n -ASGM1–treated mice, a signiﬁcant percentage of
ecipient B6.CD8/ mice rescued with 1000 AKR
SCs were reconstituted by host-derived, but not
onor-derived, hematopoiesis.
ffect of Elimination of Pathways of Cytotoxicity
Both NK and CD8 cells eliminate targets by
ommon effector mechanisms that include granule-
ediated (perforin and granzymes) and FasL-medi-
ted killing. To delineate the relative importance of
hese cytotoxic pathways on HSC resistance in this
train combination, we performed transplantations
nto C57BL/6 mice that were defective for either
erforin (B6.pfp/) or FasL (B6.gld). Titrated num-
ers of AKR/J HSCs were infused into irradiated
6.pfp/ or B6.gld recipients. Figure 4 shows that no
iscernible reduction in the barrier to engraftment
as detectable in either immune-deﬁcient mouse
train as compared with B6.WT controls. Results
igure 3. Transplantation of allogeneic HSCs into recipients lack-
ng expression of the CD8 antigen. Titrated doses of MHC-mis-
atched AKR/J HSCs were injected into lethally irradiated CD8-
eﬁcient mice (B6.CD8/). Shown is the survival of mice that
nderwent transplantation with 300, 1000, 3000, or 6000 HSCs
ompared with the survival of XRT controls (950 cGy of radiation).
esults are pooled from 2 independent experiments.ere obtained from 2 separate experiments, and P ealues are shown for the individual experiments. A
otal of 56% (P 	 .937 and .44) of perforin-deﬁcient
ice and 80% (P 	 .937 and .426) of FasL-defective
ice that underwent transplantation with 6000 HSCs
urvived 100 days after transplantation. Survival at
SC doses 
6000 was also comparable to that of
6.WT controls.
limination of Cytokines
In addition to the perforin and FasL cytotoxic
athways, NK and CD8 cells can kill or alter the
unction of target cells via production and secretion of
mmune-modulating cytokines. TNF- and TGF-
ave both been described as potentially responsible
or allogeneic hematopoietic cell resistance [36,46].
e therefore examined the role of these cytokines, as
ell as the role of Th1- and Th2-associated cytokines,
n engraftment resistance by using as recipients se-
ected cytokine knockout mice. Graded numbers of
KR/J HSCs were infused into mice that were deﬁ-
ient in either TNF- or TGF-. Alternatively, mice
eﬁcient in either the Th1-polarizing cytokine inter-
eron (IFN)– or the Th2 cytokines interleukin
IL)–4 or IL-10 served as recipients. Figure 5 dem-
igure 4. Transplantation of allogeneic HSCs into recipients with
efects in the perforin or Fas pathways. Titrated doses of MHC-
ismatched AKR/J HSCs were injected into lethally irradiated (A)
erforin-deﬁcient (B6.pfp/) or (B) FasL-defective (B6.gld) recip-
ents. Survival of mice that underwent transplantation with 300,
000, 3000, or 6000 HSCs is compared with that of XRT controls
950 cGy of radiation). Results are pooled from 2 independent
xperiments.
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Resistance to Allogeneic HSC Engraftment
Bnstrates that no reduction in the engraftment barrier
as observed in any of the cytokine-deﬁcient strains as
ompared with B6.WT mice. In fact, in many of the
mmune-deﬁcient strains (TGF-/, TNF-/,
L-4/, and IL-10/), worse survival was observed
t the 6000-HSC dose compared with B6.WT recip-
ents (TGF-/, P 	 .007; TNF-/, P 	 .004;
L-4/, P 	 .032 and .094; IL-10/, P 	 .008 and
177). For the 2 cytokine knockout recipient groups,
GF-/ and IL-10/, that did not demonstrate a
trict dose-response relationship at the 3000- and
000-HSC doses, these differences were not statisti-
ally signiﬁcant (P 	 .113 and P 	 .254, respectively).
hus, we conclude that the absence of any 1 of these
ytokines does not alter host resistance to allogeneic
igure 5. Transplantation of allogeneic HSCs into recipients defect
ere injected into lethally irradiated C57BL/6 mice defective for (A
hat underwent transplantation with 300, 1000, 3000, or 6000 HSC
re pooled from 2 independent experiments for each treatment groSCs as measured in our model system. c
B&MThimerism Analysis in Mice with Selected
mmunologic Defects
Peripheral blood chimerism analysis was measured
weeks after transplantation in all surviving recipients
rom the treatment groups described previously. Ta-
le 1 and Table 3 summarize these chimerism data.
urviving mice were deemed donor chimeras if they
ad evidence of multilineage donor cells in the pe-
ipheral blood. Although chimeric mice had evidence
f signiﬁcant levels of persistent host T cells after
ransplantation, most demonstrated 60% donor T
ells in the blood by 6 weeks. Estimates of non–T-cell
himerism were based on the percentage of donor
220 cells, which stain brightly for H-2k and which
single cytokine. Titrated doses of MHC-mismatched AKR/J HSCs
, (B) TGF-, (C) TNF-, (D) IL-4, or (E) IL-10. Survival of mice
mpared with that of XRT controls (950 cGy of radiation). Resultsive in a
) IFN-
s is coorrelate with the levels of donor granulocytes and
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8acrophages [42]. Chimerism levels in these non–T-
ell lineages were, on average, 95% by 6 weeks. Of
ote, survival did not always correlate with donor
himerism. As previously described, the most striking
xamples of differences between survival and donor
himerism occurred at the lower HSC doses in the
-ASGM1–treated mice (Table 1) and B6.CD8/
ice (Table 3). A lack of correlation between survival
nd chimerism was also noted in several of the im-
une-deﬁcient mice at higher HSC doses, including
6.pfp/, B6.gld, B6.IFN-/, and B6.IL-4/ re-
ipients (Table 3). Of note, B6.gld recipients demon-
trated resistance comparable to that of B6.WT mice
Tables 1 and 3); however, even at the highest HSC
ose level, there was no evidence of donor-derived
ematopoiesis. It therefore seems that in many of the
xperimental groups, persistent host hematopoietic
lements survived the conditioning treatment and
ere responsible for long-term reconstitution of the
lood.
ISCUSSION
Failure to engraft remains a potential life-threat-
ning complication after AHCT. Clinical and animal
tudies have shown that manipulation of hematopoi-
tic grafts can exacerbate this problem. In these stud-
es, we attempted to dissect the mechanisms by which
llogeneic HSCs are resisted by recipient immune
ells. Prior reports by us and others have shown that
ouse BM contains a non-HSC population that facil-
tates HSC engraftment [40,47]. Here, we trans-
lanted puriﬁed c-KitThy-1loLin/loSca-1 HSCs.
his allowed us to study resistance to engraftment in
he absence of other confounding graft-facilitating
opulations.
The strain combination used in this study demon-
able 3. Survival and Chimerism Analysis after Transplantation of Pu
Recipient
% Survival/% D
300 KTLS 1
6.CD8
/
0/0 (10) 5
6.pfp/ 0/0 (7) 10
6.gld 0/0 (8)
6.IFN-/ 0/0 (10)
6.TGF-/ 0/0 (10)
6.TNF-/ 0/0 (10)
6.IL-4/ 0/0 (10)
6.IL-10/ 0/0 (4)
hown are the percentage of recipients that survived for a given HSC
assessed for evidence of donor chimerism in the T- and B-
transplantation by ﬂow cytometric analysis with donor class I H2
Non–T-cell chimerism was best quantitated by -B220 staining

 5% donor type in all lineages. Data were pooled from 2 ind
lethal radiation (950 cGy).
TLS indicates c-KitThy-1loLin/loSca-1 HSCs.trated high engraftment resistance to puriﬁed HSCs Ws compared with other allogeneic strains that we have
ested, because even large doses of HSCs could not
escue 100% of lethally irradiated recipients. To es-
ablish the identity and role of immune effector cells
n this model, HSC transplantations were performed
nto either mice that were treated with -ASGM1 or
D8 cells. -ASGM1 depletes its target cells in vivo
48-51] and has been shown to block both NK cell and
TL activity after in vivo administration [43,44]. As
xpected, we found that the major population depleted
y the antibody was also positive for NK cell markers.
n addition, antibody treatment resulted in depletion
f minor populations of CD3, CD4, and CD8
ells that double-stain with -ASGM1. It is interest-
ng to note that the macrophage marker Mac-1 also
tains ASGM1 cells. However, in antibody plus
RT–treated mice, a prominent Mac-1 population
emained (Table 2), thus suggesting that this
-ASGM1Mac-1 population does not contribute
igniﬁcantly to engraftment resistance. Transplanta-
ions into B6.CD8/mice also showed a signiﬁcant
eduction in the engraftment barrier. This decrease
as not as profound as in -ASGM1–treated mice, in
greement with the observation that B6.CD8/ re-
ipients retained signiﬁcant levels of radioresistant
SGM1NK1.1 cells. Thus, in the absence of facil-
tating cells, engraftment of puriﬁed HSCs across a
trongly resistant allogeneic barrier can be achieved by
liminating or reducing radioresistant NK and/or
D8 effector cell populations.
We then sought to study the mechanism(s) by
hich effector host populations mediate this alloge-
eic HSC engraftment barrier. Disruption of either of
he 2 major cytotoxic pathways, the perforin-depen-
ent or Fas-FasL interaction, did not alter HSC re-
istance. These results were consistent with prior re-
orts in different transplantation models. Aguila and
SCs from AKR/J into B6 Immune-Defective Recipients
himerism for HSC Dose (No. Mice Analyzed)
LS 3000 KTLS 6000 KTLS
10) 70/100 (10) 90/100 (10)
10) 20/50 (10) 56/100 (9)
9) 20/0 (10) 80/0 (9)
10) 30/0 (10) 40/50 (9)
10) 10/100 (10) 0/0 (5)
10) 0/0 (10) 0/0 (4)
10) 10/0 (10) 10/100 (10)
9) 20/100 (9) 0/0 (5)
nd the percentage of these survivors that were chimeric. Mice were
d macrophage and granulocyte lineages at 6 weeks after HSC
c staining. Chimeric mice had 60% donor-derived blood T cells.
was, on average,  95% donor type. Nonchimeric recipients were
nt experiments. Recipients were prepared for transplantation withriﬁed H
onor C
000 KT
0/20 (
/100 (
0/0 (
0/0 (
0/0 (
0/0 (
0/0 (
0/0 (
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Resistance to Allogeneic HSC Engraftment
Bogeneic HSCs in transgenic mice deﬁcient in NK and
-cell cytotoxicity due to cell suicide triggered by
xpression of granzyme A. Graubert et al. [37] studied
h resistance in granzyme B–deﬁcient mice, and
aker et al. [36] tested allogeneic BM resistance in
erforin knockout mice and FasL-deﬁcient recipients.
n all 3 independent reports, it was found that impair-
ent of killing via granule exocytosis did not measur-
bly reduce the hematopoietic cell resistance. Further-
ore, the study by Baker et al. [36] and our studies
howed that FasL-deﬁcient mice also maintained
trong engraftment barriers. More recently, Komatsu
t al. [39] generated double-deﬁcient (perforin plus
asL) and triple-deﬁcient (perforin plus FasL plus
NF receptor) mice that served as recipients for he-
atopoietic cell transplants across minor histocom-
atibility barriers. Neither the double nor triple cyto-
oxic–deﬁcient mice showed a diminished capacity to
esist BM allografts as compared with wild-type recip-
ents. Of note, studies by Bennett et al. [52] compared
he need for perforin- and Fas-dependent pathways in
cute rejection of BM by NK cells in 2 different
trains (129 and C57BL/6 mice). Lack of perforin was
oted to decrease the ability of 129 mice, but not
57BL/6 mice, to reject incompatible BM. However,
his dependence on perforin was highly inﬂuenced by
he environmental housing conditions. Thus, data
rom several independent laboratories showed that
hese 2 primary mechanisms of cellular-mediated cy-
otoxicity likely do not represent the principal way
hat hematopoietic grafts are eliminated.
An alternative mechanism to perforin or Fas-FasL
athways is that secreted cytokines play the primary
ole in resisting allogeneic hematopoietic cells. Here
e used as recipients several knockout mice that were
efective in production of deﬁned cytokines and found
hat no single cytokine defect reduced the allograft
arrier. Because of prior studies suggesting that
NF-, TGF-, or IFN- has a regulatory role in
ematopoiesis [53] and/or can mediate killing of tar-
et cells, the transplantations performed into these
ytokine-deﬁcient mice were of particular interest.
NF- and IFN- have been shown to induce Fas
ntigen expression on the surface of human HSCs,
hus increasing their susceptibility to killing by anti-
as antibodies [54,55]. TNF- also has direct cyto-
oxic actions, and it was suggested that TNF- might
egulate hematopoiesis by inhibiting the growth of
arly hematopoietic cells [56-58]. Nonetheless, nei-
her the TNF-– nor IFN-–deﬁcient mice showed a
eduction in the engraftment barrier as compared with
ild-type mice. In fact, in both of these knockout
ouse strains, resistance seemed more severe, with
educed survival and reduced chimerism, respectively.
he proposed roles of TGF- have been conﬂicting.
t is thought that TGF- can mediate veto effects that
esult in the deletion of alloreactive CTLs [36,59]. c
B&MTlternatively, TGF- may act to decrease NK cell
otency by inhibiting the expression of FasL on NK
ells. The latter hypothesis suggests that TGF-–
eﬁcient mice would demonstrate increased—not re-
uced—resistance to engraftment. In our hands,
GF-–deﬁcient mice demonstrated increased resis-
ance to HSCs compared with wild-type recipients,
hich, taken together with the TNF- or IFN- data,
upports a role for these cytokines in the reduction of
arrier activity rather than its augmentation. Mice
ith selected defects in either Th1 or Th2 polarizing
ytokines similarly had either no reduction or in-
reased resistance to engraftment. It is intriguing that
ecipients lacking IL-4, IL-10, TGF-, and TNF-
emonstrated increased resistance compared with
ild-type mice. These observations suggest that se-
ected cytokine interactions may promote rather than
eter engraftment. We are currently carrying out ex-
eriments treating knockout mice with -ASGM1 to
etermine whether high levels of resistance remain in
hese cytokine-deﬁcient mice under conditions known
o optimally reduce the engraftment barrier.
One notable ﬁnding was that survival after my-
loablative XRT did not directly correlate with chi-
erism outcome in several of the experimental groups
Tables 1 and 3). The most obvious discordance was
bserved at the lower HSC dose levels in the
-ASGM1–treated or the CD8 knockout recipients,
hich demonstrated superior survival as compared
ith wild-type mice. We interpret these data to mean
hat a reduction in immune-mediated resistance al-
ows donor HSCs to provide transient rescue of
lood-forming capacity during a critical window of
ime after XRT, but that surviving endogenous HSCs
bolish the donor cells and take over the hematopoi-
tic niches. It should be emphasized that our measures
f engraftment (ie, survival and chimerism) allowed
valuation of long-term reconstitution and differed
rom assays such as splenic 125-iododeoxyuridine up-
ake, which is a short-term assay often used as a sur-
ogate for long-term engraftment [19,60]. That rare
ost HSCs can survive myeloablation and eventually
epopulate wild-type hosts is supported by a recent
tudy demonstrating that lethally irradiated mice were
escued with progenitor cells restricted to the
egakaryocyte/erythrocyte lineage [61]. Such pro-
enitor cells did not have the capacity to self-renew,
nd the radioprotected mice had 100% host-derived
ematopoiesis beyond 30 days after transplantation.
arge numbers of donor HSCs apparently (except in
he case of gld recipients) prevent the re-emergence of
ost hematopoiesis, and the importance of stem cell
ose to engraftment outcome has been already de-
cribed for syngeneic [62] and allogeneic [40,63]
ransplantations. However, it remains to be clariﬁed in
he allogeneic setting whether, in fact, donor HSCs
ompete for hematopoietic niches or give rise to pop-
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1lations that suppress host HSCs. The observation
hat even high doses of HSCs in FasL-defective gld
ice did not result in donor chimerism implies that
isruption of the Fas/FasL pathway provides protec-
ion of their HSCs from the ablative effects of XRT
nd/or provides an as yet undeﬁned advantage over
onor HSCs. Regardless, our studies reinforce the
oncept relevant to clinical transplantation that the
SC dose contained in an allogeneic hematopoietic
raft is critical for achieving sustained engraftment.
Understanding how HSCs are recognized and
esisted is a complex biological question. From our
tudies and others modeling hematopoietic resis-
ance in mice, it is evident that different cell popu-
ations contribute to resistance and that their role(s)
re inﬂuenced by multiple factors, including genetic
ismatch, graft content, recipient preparation, and
ven environmental components [52]. The fact that
e did not observe a signiﬁcant decrease in HSC
esistance by elimination of a single cytotoxic mech-
nism further supports the idea that several syner-
istic elements control HSC engraftment. Proper
omeostatic regulation of blood production is fun-
amentally important to the survival of an organ-
sm, and we believe that many of the elements that
ontrol allogeneic HSC resistance are the same as
hose that regulate physiologic hematopoiesis.
hus, unraveling how transplanted HSCs are tar-
eted and suppressed will undoubtedly contribute
o our understanding of the control of normal he-
atopoiesis and to the understanding of pathologic
tates in which endogenous hematopoiesis is sup-
ressed, such as aplastic anemia and hypoplastic
yelodysplastic syndrome.
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